COGT
Cogent Biosciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-18/100
Last price
30.11
▼ 0.27 (0.89%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
30.15
Prev close
30.38
Day high
30.34
Day low
29.94
Volume
310.03K
Market cap
$5.22B
P/E (TTM)
—
52W range
13.78 – 43.73
Day trading desk
Gap from prior close
-0.76%
Prior close 30.38
VWAP
30.14
-0.11% from price
Relative volume
0.16×
Quiet session
Session range
1.47%
29.94 – 30.38
Position in range
39%
Mid range
ATR (14D)
1.30
4.32% of price
Prior day high
31.17
PDH
Prior day low
29.70
PDL
Bid / ask spread
—
Quote not published
Session volume
308.61K
Avg 1.94M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.97%
-7.5%
1M
-14.65%
-15.8%
3M
-25.67%
-28.7%
6M
-18.51%
-33.1%
YTD
-15.23%
-28.8%
1Y
+89.37%
+74.0%
3Y
+215.29%
+134.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on COGT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+160.00K
Net buying
Buy transactions
2
205.51K shares
Sell transactions
1
45.51K shares
Net transactions
+3
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
735.93K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 27, 26 | MORRIS ARLENE M. Director |
SELL | 45.51K | $1.69M | Direct |
| Aug 27, 26 | MORRIS ARLENE M. Director |
CONVERSION | 45.51K | $245.50K | Direct |
| May 19, 26 | ROBBINS ANDREW R. Chief Executive Officer |
STOCK | 160.00K | $0 | Direct |
| Jan 22, 26 | FAIRMOUNT FUNDS MANAGEMENT LLC Director |
SELL | 3.50M | $127.40M | Indirect |
| Dec 26, 25 | KEARNS EVAN D J.D. Officer |
SELL | 65.00K | $2.52M | Direct |
| Dec 26, 25 | GREEN JOHN L Chief Financial Officer |
SELL | 77.00K | $2.98M | Direct |
| Dec 26, 25 | SACHS JESSICA M.D. Officer |
SELL | 82.64K | $3.20M | Direct |
| Dec 26, 25 | ROBINSON JOHN EDWARD Officer |
SELL | 90.00K | $3.49M | Direct |
| Dec 17, 25 | ROBBINS ANDREW R. Chief Executive Officer |
STOCK | 1.02M | $0 | Direct |
| Dec 17, 25 | KEARNS EVAN D J.D. Officer |
STOCK | 300.00K | $0 | Direct |
| Dec 17, 25 | GREEN JOHN L Chief Financial Officer |
STOCK | 350.00K | $0 | Direct |
| Dec 17, 25 | SACHS JESSICA M.D. Officer |
STOCK | 370.00K | $0 | Direct |
| Dec 17, 25 | ROBINSON JOHN EDWARD Officer |
STOCK | 370.00K | $0 | Direct |
| Dec 17, 25 | PINNOW COLE Officer |
STOCK | 264.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FAIRMOUNT FUNDS MANAGEMENT LLC |
Director | — | Sale |
GREEN JOHN L |
Chief Financial Officer | 131.83K | Sale |
KEARNS EVAN D J.D. |
Officer | 109.40K | Sale |
MORRIS ARLENE M. |
Director | 0 | Sale |
PINNOW COLE |
Officer | 216.65K | Stock Award(Grant) |
ROBBINS ANDREW R. |
Chief Executive Officer | 657.50K | Stock Gift |
ROBINSON JOHN EDWARD |
Officer | 140.00K | Sale |
SACHS JESSICA M.D. |
Officer | 133.94K | Sale |
Fundamentals
Market cap$5.22B
Enterprise value$4.79B
Revenue (TTM)—
Gross profit—
EBITDA$-386.46M
Net income$-377.18M
EPS (TTM)$-2.16
Free cash flow$-186.15M
Total cash$792.30M
Total debt$244.26M
Book value / share$2.72
Shares outstanding173.52M
Float172.56M
Short % of float10.50%
Dividend yield0.00%
Beta (5Y)0.31
Valuation & profitability ratios
Trailing P/E—
Forward P/E-27.08
PEG ratio—
Price / sales—
Price / book11.05
EV / revenue—
EV / EBITDA-12.39
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-109.74%
Return on assets-43.84%
Debt / equity45.88
Current ratio13.57
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $269.78M | $232.66M | $173.75M | $121.63M | +16.0% |
| Selling, general & admin | $63.58M | $43.28M | $34.38M | $26.21M | +46.9% |
| Total operating expense | $333.36M | $275.94M | $208.13M | $147.84M | +20.8% |
| Operating income | -$333.36M | -$275.94M | -$208.13M | -$147.84M | -20.8% |
| Net interest income | $11.63M | $18.09M | $13.08M | $3.99M | -35.7% |
| Pre-tax income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -28.6% |
| Net income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -28.6% |
| Net income to common | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -28.6% |
| Basic EPS | -2.04 | -2.32 | -2.42 | -2.39 | +11.8% |
| Diluted EPS | -2.04 | -2.32 | -2.42 | -2.39 | +11.8% |
| EBIT | -$325.88M | -$255.86M | -$192.41M | -$147.84M | -27.4% |
| EBITDA | -$321.29M | -$251.51M | -$188.82M | -$141.96M | -27.7% |
| Basic shares | 160.98M | 110.46M | 79.66M | 58.74M | +45.7% |
| Diluted shares | 160.98M | 110.46M | 79.66M | 58.74M | +45.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $312.01M | $98.17M | $53.23M | $139.89M | +217.8% |
| Cash & short-term investments | $900.76M | $287.08M | $265.71M | $259.28M | +213.8% |
| Total current assets | $910.36M | $296.47M | $270.77M | $264.97M | +207.1% |
| Property, plant & equipment | $23.54M | $26.56M | $30.34M | $31.10M | -11.4% |
| Total assets | $937.61M | $327.90M | $313.44M | $300.81M | +185.9% |
| Total current liabilities | $63.95M | $55.71M | $38.17M | $26.85M | +14.8% |
| Long-term debt | $222.90M | — | — | — | — |
| Total debt | $238.80M | $17.47M | $18.85M | $19.65M | +1,267.1% |
| Total liabilities | $301.24M | $71.61M | $55.63M | $45.08M | +320.7% |
| Retained earnings | -$1.19B | -$859.48M | -$603.62M | -$411.21M | -38.3% |
| Shareholder equity | $636.37M | $256.29M | $257.80M | $255.74M | +148.3% |
| Working capital | $846.40M | $240.76M | $232.60M | $238.12M | +251.6% |
| Net tangible assets | $636.37M | $256.29M | $257.80M | $255.74M | +148.3% |
| Shares issued | 160.98M | 110.46M | 86.12M | 69.89M | +45.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -28.6% |
| Depreciation & amortisation | $4.58M | $4.35M | $3.59M | $5.88M | +5.3% |
| Stock-based compensation | $46.08M | $39.74M | $30.62M | $18.37M | +16.0% |
| Change in working capital | $8.01M | $11.60M | $11.44M | $751.00K | -30.9% |
| Operating cash flow | -$264.44M | -$207.79M | -$153.62M | -$118.64M | -27.3% |
| Capital expenditure | -$1.55M | -$573.00K | -$2.80M | -$6.86M | -171.2% |
| Investing cash flow | -$399.53M | $38.28M | -$97.82M | -$124.72M | -1,143.8% |
| Financing cash flow | $878.23M | $214.45M | $163.54M | $163.56M | +309.5% |
| Free cash flow | -$266.00M | -$208.36M | -$156.42M | -$125.50M | -27.7% |
| End cash position | $312.43M | $98.17M | $53.23M | $141.14M | +218.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $70.81M | $75.36M | $75.56M | $68.99M | $62.20M | -6.0% |
| Selling, general & admin | $31.83M | $28.24M | $23.93M | $14.37M | $13.38M | +12.7% |
| Total operating expense | $102.64M | $103.61M | $99.49M | $83.36M | $75.58M | -0.9% |
| Operating income | -$102.64M | -$103.61M | -$99.49M | -$83.36M | -$75.58M | +0.9% |
| Net interest income | $6.24M | $6.39M | $4.19M | $2.43M | $2.06M | -2.4% |
| Pre-tax income | -$96.41M | -$97.35M | -$102.49M | -$80.93M | -$73.53M | +1.0% |
| Net income | -$96.41M | -$97.35M | -$102.49M | -$80.93M | -$73.53M | +1.0% |
| Net income to common | -$96.41M | -$97.35M | -$102.49M | -$80.93M | -$73.53M | +1.0% |
| Basic EPS | -0.52 | -0.53 | -0.64 | -0.58 | -0.65 | +1.9% |
| Diluted EPS | -0.52 | -0.53 | -0.64 | -0.58 | -0.65 | +1.9% |
| EBIT | -$95.19M | -$96.14M | -$101.20M | -$79.47M | -$73.22M | +1.0% |
| EBITDA | -$93.82M | -$94.98M | -$100.06M | -$78.32M | -$72.06M | +1.2% |
| Basic shares | 171.01M | 162.19M | 160.98M | 139.83M | 113.93M | +5.4% |
| Diluted shares | 171.01M | 162.19M | 160.98M | 139.83M | 113.93M | +5.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $181.17M | $241.21M | $312.01M | $125.30M | $127.60M | -24.9% |
| Cash & short-term investments | $792.30M | $866.38M | $900.76M | $390.89M | $237.85M | -8.6% |
| Total current assets | $804.82M | $877.80M | $910.36M | $397.24M | $245.01M | -8.3% |
| Property, plant & equipment | $27.37M | $22.85M | $23.54M | $23.86M | $24.95M | +19.8% |
| Total assets | $834.55M | $903.01M | $937.61M | $425.93M | $274.82M | -7.6% |
| Total current liabilities | $59.30M | $57.98M | $63.95M | $62.25M | $58.42M | +2.3% |
| Long-term debt | $223.46M | $223.17M | $222.90M | $44.25M | $43.95M | +0.1% |
| Total debt | $244.26M | $238.65M | $238.80M | $60.56M | $60.66M | +2.3% |
| Total liabilities | $302.16M | $295.31M | $301.24M | $123.47M | $119.78M | +2.3% |
| Retained earnings | -$1.38B | -$1.29B | -$1.19B | -$1.09B | -$1.00B | -7.5% |
| Shareholder equity | $532.39M | $607.69M | $636.37M | $302.46M | $155.04M | -12.4% |
| Working capital | $745.52M | $819.82M | $846.40M | $335.00M | $186.59M | -9.1% |
| Net tangible assets | $532.39M | $607.69M | $636.37M | $302.46M | $155.04M | -12.4% |
| Shares issued | 171.60M | 170.77M | 160.98M | 139.83M | 113.93M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$96.41M | -$97.35M | -$102.49M | -$80.93M | -$73.53M | +1.0% |
| Depreciation & amortisation | $1.37M | $1.16M | $1.14M | $1.15M | $1.16M | +18.5% |
| Stock-based compensation | $17.11M | $16.91M | $15.75M | $10.60M | $9.72M | +1.2% |
| Change in working capital | $1.34M | -$6.83M | $132.00K | $4.76M | $7.83M | +119.6% |
| Operating cash flow | -$77.27M | -$86.88M | -$79.11M | -$64.29M | -$54.54M | +11.1% |
| Capital expenditure | -$370.00K | -$449.00K | -$811.00K | -$65.00K | -$131.00K | +17.6% |
| Investing cash flow | $14.28M | -$36.46M | -$322.77M | -$155.05M | $8.91M | +139.2% |
| Financing cash flow | $2.96M | $52.54M | $588.67M | $217.37M | $47.23M | -94.4% |
| Free cash flow | -$77.64M | -$87.33M | -$79.92M | -$64.35M | -$54.67M | +11.1% |
| End cash position | $181.59M | $241.62M | $312.43M | $125.63M | $127.60M | -24.8% |
Options analytics
Put / call volume
3.07
Put-heavy session
Put / call open interest
0.30
Positioning, not flow
Max pain
32.00
+6.3% from spot
ATM implied vol
98.4%
Nearest strike to spot
Skew (10% OTM)
-1.2%
Calls bid over puts
Call volume
67
Contracts, this expiry
Put volume
206
Contracts, this expiry
Heaviest call OI
35.00
1.51K contracts
Heaviest put OI
30.00
412 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.56 | -0.52 | +8.0% |
| Mar 2026 | -0.54 | -0.53 | +1.9% |
| Dec 2025 | -0.51 | -0.56 | -10.5% |
| Sep 2025 | -0.52 | -0.50 | +3.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.55 | 8 | $0 | 0.0% |
| Next quarter | -0.58 | 8 | $5.99M | 0.0% |
| Current year | -2.21 | 9 | $5.99M | 0.0% |
| Next year | -1.11 | 8 | $292.82M | +4,789.6% |
Analyst targets & ownership
Mean target$55.82
High target$62.00
Low target$45.00
Implied upside85.38%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy2 / 9
Hold1
Sell / Strong sell0 / 0
Held by insiders0.42%
Held by institutions115.22%
Institutions holding438
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
31.33
-3.88% from price
SMA 20
32.01
-5.93% from price
SMA 50
35.43
-15.03% from price
SMA 100
35.72
-15.71% from price
SMA 200
36.24
-16.92% from price
EMA 12
31.40
-4.10% from price
EMA 26
32.68
-7.86% from price
EMA 50
34.17
-11.87% from price
RSI (14)
31.1
Neutral
MACD (12,26,9)
-1.28
Hist -0.01
ATR (14)
1.30
4.32% of price
Realised vol 30D
33.0%
Annualised
Bollinger upper
34.04
20, 2σ
Bollinger lower
29.97
20, 2σ
50 / 200 cross
Death
35.43 vs 36.24
Trend bias
Below 200
-16.92%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.40
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
33.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-29.7%
Peak to trough
Max drawdown 5Y
-76.3%
Peak to trough
ATR 14
1.30
4.32% of price
Beta (reported)
0.31
5Y monthly, from filing
Short interest
Shares short
18.13M
Prior 18.41M
Change vs prior
-1.5%
Shorts covering
% of float
10.50%
Elevated
% of shares out
10.45%
Against total outstanding
Days to cover
11.5
Crowded exit
Float
172.56M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 12, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| May 29, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 17, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Feb 18, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jan 21, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jan 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 19, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Dec 8, 25 | Needham | MAINTAINED | Hold | Hold |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay dateNov 9, 2020
Last split1:4
Split dateNov 9, 2020
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-02
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-05-05
Annual Report to Shareholders
ARS · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-02-17
Corporate Changes & Voting Matters
8-K · 2025-12-08
Corporate Changes & Voting Matters
8-K · 2025-11-18
Headlines
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
Simply Wall St. · 12d ago
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
Simply Wall St. · 13d ago
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
Simply Wall St. · 13d ago
Cogent Biosciences Gets US FDA Acceptance for Bezuclastinib AdvSM Application
MT Newswires · 22d ago
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
GlobeNewswire · 22d ago
Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia
MT Newswires · 35d ago
Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing
MT Newswires · 37d ago
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.